The duration between the onset of neurological symptoms and first medical evaluation differed significantly between the three polyneuropathy groups, patients with anti-MAG antibodies having the longest duration of symptoms (19 months), followed by patients with CIDP (6.5 months), and by those with d-CIDP (3 months), χ2(2) = 8.942, p = 0.011. This evidence concerns the gene PMP22 and polyneuropathy.